Bolt Biotherapeutics, Inc. Stock News

Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Toll-Like Receptor Agonist treatment scenario include InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences, Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics, Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and many others.

Penny stocks are incredibly risky and should only be considered with speculation funds. Still, these names could swing higher for investors.

Bolt Biotherapeutics Inc (BOLT) shares closed this week 22.9% lower than it did at the end of last week. The stock is currently down 22.9% year-to-date, down 88.2% over the past 12 months, and down 88.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $4.99 and as low as $3.65 this week.Shares closed 91.2% below its 52-week high and 3.6% above its 52-week low.Trading volume this week was 48.4% higher than the 10-day average and 42.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -286.2% The company's stock price performance over the past 12 months lags the peer average by 500.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the first patient has been dosed in a new combination arm of the ongoing multi-center, multi-dose Phase 1/2 clinical trial of BDC-1001. This arm is evaluating BDC-1001 in combination with Bristol Myers Squibb''s PD-1 checkpoint inhibitor OPDIVO® (nivolumab). In parallel, Bolt continues to advance the single-agent portion of the study, following the presentation of interim dose-escalation data at the European Society of Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021. BDC-1001 is a HER2-targeting Boltbody immune-stimulating antibody conjugate (ISAC) (trastuzumab biosimilar conjugated to a toll-like receptor 7 and 8 agonist) in development for the treatment of patients with HER2-expressing solid tumors. "We are excited to evaluate BDC-1001 in combination with nivolumab, a leading PD-1 checkpoint inhibitor.

Bolt Biotherapeutics Inc (BOLT) shares closed today 10.5% higher than it did at the end of yesterday. The stock is currently down 84.6% year-to-date, down 84.6% over the past 12 months, and down 84.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $5.15 and as low as $4.31 this week.Shares closed 88.5% below its 52-week high and 24.7% above its 52-week low.Trading volume this week was 4.4% lower than the 10-day average and 62.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 587.6% The company's stock price performance over the past 12 months lags the peer average by 577.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

At least one of the three could be in store for better news in the future.

REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointment of Nicole Onetto, M.D., to its Board of Directors effective Dec. 14, 2021.

SVB Leerink reaffirmed their buy rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research report report published on Thursday morning, Price Targets.com reports. A number of other research analysts have also weighed in on BOLT. Zacks Investment Research raised Bolt Biotherapeutics from a sell rating to a hold rating in a research report on […] The post SVB Leerink Reaffirms Buy Rating for Bolt Biotherapeutics (NASDAQ:BOLT) appeared first on ETF Daily News .

Bolt Biotherapeutics (NASDAQ:BOLT) had its price objective increased by Stifel Nicolaus from $19.00 to $34.00 in a research report report published on Monday morning, The Fly reports. Stifel Nicolaus currently has a buy rating on the stock. The analysts noted that the move was a valuation call. A number of other equities analysts also recently []

Bolt Biotherapeutics (NASDAQ:BOLT) had its price objective lifted by Stifel Nicolaus from $19.00 to $34.00 in a research note issued to investors on Monday, The Fly reports. They currently have a buy rating on the stock. The analysts noted that the move was a valuation call. Several other equities research analysts have also commented on []

The company announced disappointing interim data from a phase 1/2 study of its lead cancer program.

Bolt Biotherapeutics Inc (NASDAQ: BOLT ) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to an innovative TLR7/8 agonist. The data were shared at the European Society for Medical Oncology Immuno-Oncology (ESMO Full story available on Benzinga.com